Business Context and Reporting Period
This Form 8-K was filed by Illumina, Inc. on January 9, 2008, reporting a material definitive agreement entered into on the same date. The filing addresses the resolution of ongoing patent litigation between Illumina and Affymetrix, Inc.
Key Financial Metrics
The filing discloses a specific financial obligation resulting from the settlement agreement:
- Settlement Payment: Illumina agreed to a one-time payment of $90 million to Affymetrix.
- Liability Admission: The payment was made without admitting liability.
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes
The primary material change is the cessation of pending patent litigation in the United States (District of Delaware), Germany (Regional Court in Düsseldorf), and the United Kingdom (High Court of Justice, London). Previously, Affymetrix alleged infringement regarding Illumina's Array Matrix, BeadChip, and Genome Analyzer products. Both parties agreed to dismiss their respective lawsuits and counterclaims with prejudice.
Outlook, Risks, and Contingencies
Settlement Terms and Future Protection:
- Covenant Not to Sue: Affymetrix agreed not to sue Illumina, its affiliates, or customers under any Affymetrix patents for current products, products in development, and evolutions thereof.
- Future Technology: Affymetrix agreed not to sue for four years regarding products based on future technology developments.
- Exclusions: The covenants do not cover the field of photolithography, a process used by Affymetrix to manufacture arrays, in which Illumina does not currently operate.
Documentation: The full terms and conditions of the settlement agreement will be filed as an exhibit to Illumina's Annual Report on Form 10-K for the fiscal year ending December 30, 2007.
Investor Verification Checklist
- Verify the impact of the $90 million one-time payment on the company's cash position and earnings for the fiscal year ending December 30, 2007.
- Review the full settlement agreement in the upcoming Form 10-K to understand any additional covenants or conditions not detailed in this summary.
- Confirm that no other patent litigation remains pending between the two parties outside the scope of this settlement.